Key Takeaways TLRY rose 44.1% on Friday after reports that an executive order could reclassify marijuana under federal law.Tilray Brands rallied as the reclassification could ease banking limits, tax burdens and investment barriers.Before the surge, TLRY was down 36.6% YTD, highlighting how quickly sentiment shifts on reform signals.Shares of cannabis producer Tilray Brands, Inc. (TLRY) surged 44.1% on Friday, Dec. 12, 2025, on reports that President Donald Trump is expected to sign an executive order as ea ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Cronos Group (CRON) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Cronos Group is a member of our Medical group, which includes 947 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector ...

It has been about a month since the last earnings report for Ironwood Pharmaceuticals (IRWD) . Shares have added about 24.9% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ironwood due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Ironwood Pharmaceuticals, Inc. before we dive into how investors and analysts have reacted as of late ...

文章核心观点 - 文章聚焦于医疗板块股票表现 指出Aurinia Pharmaceuticals和Cardinal Health是其中表现优异的公司 其年初至今的股价回报率远超行业平均水平 并且两家公司均获得Zacks买入评级 盈利预期被上调 [1][4][6] 公司表现与评级 - Aurinia Pharmaceuticals年初至今股价回报率约为72.9% 远超医疗板块公司平均3.9%的回报率 [4] - 过去90天内 市场对Aurinia Pharmaceuticals全年盈利的共识预期上调了20.3% 公司当前Zacks评级为2（买入） [3] - Cardinal Health年初至今股价回报率为67.4% 同样跑赢医疗板块 [4] - 过去三个月内 市场对Cardinal Health当前财年的每股收益共识预期上调了4.4% 该股当前Zacks评级也为2（买入） [5] 行业背景与比较 - 医疗板块在Zacks的16个行业组别中排名第5 该板块包含947家公司 [2] - Aurinia Pharmaceuticals所属的医疗-药品行业包含146只个股 在Zacks行业排名中位列第84 该行业股票今年平均上涨5% [5] - Cardinal Health所属的医疗-牙科供应行业包含14只个股 在Zacks行业排名中位列第99 该行业年初至今上涨9.1% [6]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

文章核心观点 - 文章探讨了动量投资策略 并重点分析了Nektar Therapeutics (NKTR)作为符合该策略的潜力标的 其拥有出色的动量风格评分和积极的股价及盈利预测修正趋势 [1][2][3][4][12] 动量投资与评分体系 - 动量投资的核心是追随股票近期的价格趋势 旨在通过“买高卖更高”来获取及时且盈利的交易 [1] - Zacks动量风格评分是用于帮助定义和量化股票动量的工具 它作为Zacks评级系统的补充 [2][4] - 研究表明 同时获得Zacks Rank 1或2评级以及动量风格评分A或B的股票 在接下来的一个月内表现会超越市场 [4] Nektar Therapeutics (NKTR) 动量表现分析 - 公司当前Zacks Rank评级为2 (买入) 动量风格评分为A [3][4][12] - 短期股价表现强劲 过去一周股价上涨20.14% 远超同期Zacks医疗-药品行业4.47%的涨幅 [6] - 月度股价表现亦优于行业 过去一个月上涨1.66% 而行业平均涨幅为0.88% [6] - 中长期股价表现极为突出 过去一个季度股价上涨16.89% 过去一年大幅上涨272.08% 同期标普500指数仅分别上涨6.25%和14.29% [7] - 过去20个交易日的平均成交量为603,538股 为评估价格与成交量关系提供了基准 [8] 盈利预测修正 - 盈利预测修正是动量风格评分和Zacks评级的重要组成部分 [9] - 过去两个月内 对本财年全年盈利预测有2次向上修正 无向下修正 共识预期从每股亏损12.37美元改善至每股亏损10.87美元 [10] - 对于下一财年 同期内有5次盈利预测向上修正 无向下修正 [10]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

文章核心观点 - Alpha Cognition Inc (ACOG) 年初至今的股价表现优于其所在的医疗板块整体水平 但略逊于其所属的细分生物医学与遗传学行业平均水平 [1][4][6] - 另一家医疗股 Actinium Pharmaceuticals (ATNM) 年初至今表现强劲 涨幅远超板块及自身行业平均水平 [5][7] 公司表现与评级 - Alpha Cognition Inc (ACOG) 当前Zacks Rank评级为2 (买入) [3] - 过去三个月 市场对ACOG全年收益的共识预期上调了30% [4] - 自年初以来 ACOG股价上涨约8.2% [4] - Actinium Pharmaceuticals (ATNM) 当前Zacks Rank评级同样为2 (买入) [5] - 过去三个月 市场对ATNM全年每股收益(EPS)的共识预期上调了11.7% [5] - 自年初以来 ATNM股价上涨了15.1% [5] 行业与板块比较 - 医疗板块包含950只个股 当前Zacks板块排名为第4位 [2] - 年初至今 医疗板块股票平均上涨6.5% ACOG的8.2%涨幅优于板块平均水平 [4] - ACOG所属的医疗-生物医学与遗传学行业包含467只个股 当前Zacks行业排名为第91位 [6] - 年初至今 该行业股票平均上涨19.9% ACOG的8.2%涨幅略低于行业平均水平 [6] - ATNM所属的医疗-药品行业包含147只个股 当前Zacks行业排名为第79位 [7] - 年初至今 该行业整体上涨7.9% ATNM的15.1%涨幅远超其行业平均水平 [5][7]

公司表现与排名 - Guardant Health当前年度至今回报率约为246.8%，远超医疗板块7%的平均回报率[4] - Guardant Health目前拥有Zacks Rank 2评级[3] - Guardant Health全年收益的Zacks共识预期在过去一个季度内上调了3.7%[3] 行业比较 - 医疗板块在Zacks行业排名中位列第3，包含950家公司[2] - Guardant Health所属的医疗-生物医学和遗传学行业包含467只股票，在Zacks行业排名中位列第77，该行业股票今年平均上涨20%[5] - 医疗板块中另一只股票Collegium Pharmaceutical年度至今回报率为67%[4] 同业公司对比 - Collegium Pharmaceutical拥有Zacks Rank 1评级[5] - Collegium Pharmaceutical当前年度共识每股收益预期在过去三个月内上调了9.1%[5] - Collegium Pharmaceutical所属的医疗-药品行业包含147只股票，在Zacks行业排名中位列第69，该行业今年至今上涨7.7%[6]

股价表现 - 公司股价近期表现强劲，过去一个月上涨33.5%，并创下52周新高48.37美元 [1] - 公司年初至今股价上涨67%，远超医疗板块7%和医药行业7.7%的涨幅 [1] - 公司同行Catalyst Pharmaceuticals过去一个月股价上涨8% [12] 财务业绩与预期 - 公司在过去四个季度均超出盈利预期，最近一期财报每股收益2.25美元，超出共识预期1.88美元，收入超出共识预期10.35% [2] - 本财年预期每股收益7.55美元，收入7.8393亿美元，分别同比增长17.05%和24.15% [3] - 下一财年预期每股收益7.4美元，收入8.0727亿美元，分别同比变化-2.03%和2.98% [3] - 同行Catalyst Pharmaceuticals上一季度盈利超出共识预期33.33%，本财年预期每股收益2.54美元，收入5.7638亿美元 [11] 估值指标 - 公司基于当前财年每股收益预期的市盈率为6.3倍，远低于同行平均的19.3倍 [7] - 公司基于 trailing cash flow 的市现率为3.9倍，远低于同行平均的15.9倍 [7] - 同行Catalyst Pharmaceuticals的预期市盈率为9.54倍，市现率为9.44倍 [12] 投资评级与评分 - 公司获得Zacks 1（强力买入）评级，得益于盈利预期的上调 [8] - 公司的价值评分为A，增长评分为D，动量评分为C，综合VGM评分为B [6] - 同行Catalyst Pharmaceuticals获得Zacks 2（买入）评级，价值评分为A，增长评分为C，动量评分为F [10] 行业背景 - 医药行业位列所有行业的前28%，为行业内公司提供了有利的行业环境 [12]